Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Liabilities and Shareholders Equity (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Liabilities and Shareholders Equity data on record, last reported at $190.8 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 11.66% year-over-year to $190.8 million; the TTM value through Dec 2025 reached $572.0 million, down 26.08%, while the annual FY2024 figure was $212.8 million, 63.24% up from the prior year.
  • Liabilities and Shareholders Equity reached $190.8 million in Q3 2025 per CTNM's latest filing, up from $182.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $221.4 million in Q2 2024 and bottomed at $123.6 million in Q1 2024.
  • Average Liabilities and Shareholders Equity over 3 years is $184.5 million, with a median of $194.6 million recorded in 2025.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 63.24% in 2024, then dropped 17.38% in 2025.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $130.4 million in 2023, then soared by 63.24% to $212.8 million in 2024, then decreased by 10.34% to $190.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $190.8 million in Q3 2025, $182.9 million in Q2 2025, and $198.3 million in Q1 2025.